Breaking News Instant updates and real-time market news.

BHVN

Biohaven Pharmaceutical

$47.28 /

+3.03 (+6.85%)

07:51
05/18/20
05/18
07:51
05/18/20
07:51

Biohaven Pharmaceutical to present Nurtec data at AAN virtual platform

Biohaven Pharmaceutical announced that it will present data from 25 accepted abstracts demonstrating the efficacy, safety, tolerability and pharmacoeconomic value of Nurtec on the 2020 American Academy of Neurology, or AAN, virtual platform. Nurtec ODT is the first and only calcitonin gene-related peptide, or CGRP, receptor antagonist in an orally disintegrating tablet, or ODT, approved by the FDA for the acute treatment of migraine in adults. Notably, Biohaven will be presenting results from the rimegepant Phase 3 and long-term safety clinical trials highlighting rimegepant's rapid onset and sustained duration of action, favorable long-term safety profile, concomitant use with anti-CGRP monoclonal antibodies, efficacy in triptan-experienced patients, reduction in monthly migraine days and improvements in productivity. A total of 25 posters/presentations will be presented as part of the AAN virtual platform. Concomitant use of rimegepant with anti-CGRP mAbs was evaluated in a subgroup of patients in the rimegepant long-term safety study. Thirteen patients who experienced two to eight moderate-to-severe monthly attacks while taking a stable dose of an FDA-approved anti-CGRP mAb were included and instructed to treat attacks of any pain intensity with oral rimegepant 75 mg as needed up to once daily for 12 weeks. The study demonstrated favorable tolerability and no safety issues when using rimegepant as an oral acute treatment in adults with migraine while also receiving an injectable anti-CGRP mAb preventive treatment. A pooled analysis from three Phase 3 clinical trials evaluated the efficacy of rimegepant 75 mg in patients who had a history of triptan treatment failure or who were using triptans at the time of trial enrollment. Results demonstrated that in both groups of triptan-experienced patients, rimegepant was more effective than placebo on pain freedom, MBS freedom, and pain relief at two hours post-dose as well as other clinically meaningful secondary endpoints. Pooled results from three Phase 3 clinical trials with 3,507 patients evaluating the efficacy of rimegepant for the acute treatment of migraine showed that a single oral dose of rimegepant 75 mg without repeat dosing or rescue medication was superior to placebo for sustained pain relief and ability to function normally from two to 48 hours post-dose. Additionally, rapid onset of action was demonstrated with rimegepant ODT with some patients experiencing pain relief as early as 15 minutes post-dose; effects were statistically superior to placebo on pain relief and ability to function normally at 60 minutes post-dose. A pooled, post-hoc analysis of long-term safety data demonstrated that acute treatment of migraine with rimegepant 75 mg provides significant improvements to absenteeism, presenteeism and improves lost productivity time by 44% reflecting improvements in workplace productivity. In the study, patients were instructed to treat migraine attacks of any pain intensity with up to one dose of rimegepant 75 mg as needed, up to once daily, for 52 weeks. ABS, PRE and LPT were assessed at baseline and at weeks 12, 24, 36, and 52 using the validated Migraine Disability Assessment instrument. Results from post-hoc, pooled analysis of long-term safety data showed a reduction in monthly migraine days, or MMD, across three rimegepant patient groups: Group 1 had 2-8 MMD and received as needed dosing, Group 2 had 9-14 MMD and also received PRN, and Group 3 had 4-14 MMD and dosed every other day plus PRN. Results showed that treatment with rimegepant 75 mg was associated with notable reductions in MMD. The magnitude of MMD reduction was associated with the range of reported historic migraine frequency and the migraine frequency assessed during the 30-day pre-treatment observation period.

BHVN Biohaven Pharmaceutical
$47.28 /

+3.03 (+6.85%)

05/11/20 Cantor Fitzgerald
Biohaven Pharmaceutical price target raised to $82 from $75 at Cantor Fitzgerald
04/17/20 Cowen
Cowen initiates Biohaven Pharmaceutical with Outperform on migraine opportunity
04/17/20 Cowen
Biohaven Pharmaceutical initiated with an Outperform at Cowen
03/31/20 Oppenheimer
Biohaven Pharmaceutical price target lowered to $37 from $48 at Oppenheimer

TODAY'S FREE FLY STORIES

Hot Stocks
UPS CEO: Our customers want a digital experience » 18:38
10/28/20
10/28
18:38
10/28/20
18:38
UPS

UPS

$155.75 /

-15.38 (-8.99%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
UPS UPS
$155.75 /

-15.38 (-8.99%)

UPS UPS
$155.75 /

-15.38 (-8.99%)

10/27/20 UBS
UPS upgraded to Buy from Neutral at UBS
10/21/20 Oppenheimer
UPS price target raised to $186 from $153 at Oppenheimer
10/16/20 Barclays
UPS price target raised to $160 from $135 at Barclays
10/14/20 Citi
UPS price target raised to $190 from $150 at Citi
UPS UPS
$155.75 /

-15.38 (-8.99%)

UPS UPS
$155.75 /

-15.38 (-8.99%)

UPS UPS
$155.75 /

-15.38 (-8.99%)

UPS UPS
$155.75 /

-15.38 (-8.99%)

Periodicals
Facebook may be drawn into U.K. legal dispute over data misuse, Bloomberg says » 18:30
10/28/20
10/28
18:30
10/28/20
18:30
FB

Facebook

$267.62 /

-15.67 (-5.53%)

Facebook risks being…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FB Facebook
$267.62 /

-15.67 (-5.53%)

FB Facebook
$267.62 /

-15.67 (-5.53%)

08:31 Today JPMorgan
Facebook price target raised to $315 from $300 at JPMorgan
10/26/20 KeyBanc
Facebook price target raised to $340 from $330 at KeyBanc
10/26/20 Mizuho
Facebook price target raised to $330 from $315 at Mizuho
10/22/20 Argus
Snap price target raised to $50 from $30 at Argus
FB Facebook
$267.62 /

-15.67 (-5.53%)

FB Facebook
$267.62 /

-15.67 (-5.53%)

FB Facebook
$267.62 /

-15.67 (-5.53%)

FB Facebook
$267.62 /

-15.67 (-5.53%)

Hot Stocks
Bed Bath & Beyond CEO: We are generating cash, we're very liquid » 18:27
10/28/20
10/28
18:27
10/28/20
18:27
BBBY

Bed Bath & Beyond

$21.10 /

-2.91 (-12.12%)

In an interview on…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

10/21/20 Baird
Bed Bath & Beyond could double again if targets achieved, says Baird
10/14/20 Raymond James
Bed Bath & Beyond price target raised to $26 from $22 at Raymond James
10/06/20 Loop Capital
Bed Bath & Beyond price target raised to $20 from $18 at Loop Capital
10/06/20 Goldman Sachs
Bed Bath & Beyond price target raised to $12 from $5 at Goldman Sachs
BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

BBBY Bed Bath & Beyond
$21.10 /

-2.91 (-12.12%)

Periodicals
Spotify draws criticism over Alex Jones claims on Rogan podcast, Bloomberg says » 18:24
10/28/20
10/28
18:24
10/28/20
18:24
SPOT

Spotify

$276.35 /

-11.34 (-3.94%)

Spotify is being…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SPOT Spotify
$276.35 /

-11.34 (-3.94%)

SPOT Spotify
$276.35 /

-11.34 (-3.94%)

10/27/20 Morgan Stanley
Spotify price target raised to $300 from $275 at Morgan Stanley
10/27/20 Deutsche Bank
Spotify price target raised to $250 from $240 at Deutsche Bank
10/14/20 Barclays
Spotify price target raised to $320 from $310 at Barclays
10/06/20 Credit Suisse
Sirius XM upgraded to Outperform from Neutral at Credit Suisse
SPOT Spotify
$276.35 /

-11.34 (-3.94%)

SPOT Spotify
$276.35 /

-11.34 (-3.94%)

SPOT Spotify
$276.35 /

-11.34 (-3.94%)

SPOT Spotify
$276.35 /

-11.34 (-3.94%)

Earnings
Suncor Energy reports Q3 operating EPS (C$0.20) vs C$0.72 last year » 18:22
10/28/20
10/28
18:22
10/28/20
18:22
SU

Suncor

$11.27 /

-0.735 (-6.12%)

Suncor states: "The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SU Suncor
$11.27 /

-0.735 (-6.12%)

SU Suncor
$11.27 /

-0.735 (-6.12%)

08:20 Today Citi
Suncor downgraded to Neutral from Buy at Citi
10/26/20 CIBC
Suncor initiated with an Outperformer at CIBC
10/20/20 Morgan Stanley
Suncor price target lowered to C$22 from C$31 at Morgan Stanley
10/16/20 National Bank
Suncor price target lowered to C$21 from C$28 at National Bank
SU Suncor
$11.27 /

-0.735 (-6.12%)

SU Suncor
$11.27 /

-0.735 (-6.12%)

SU Suncor
$11.27 /

-0.735 (-6.12%)

Syndicate
Cancer Genetics announces $2M bought deal offering » 17:54
10/28/20
10/28
17:54
10/28/20
17:54
CGIX

Cancer Genetics

$3.43 /

-0.27 (-7.30%)

Cancer Genetics announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CGIX Cancer Genetics
$3.43 /

-0.27 (-7.30%)

CGIX Cancer Genetics
$3.43 /

-0.27 (-7.30%)

CGIX Cancer Genetics
$3.43 /

-0.27 (-7.30%)

Earnings
Forterra sees FY20 adjusted EBITDA $265M-$280M » 17:53
10/28/20
10/28
17:53
10/28/20
17:53
FRTA

Forterra

$14.12 /

-0.79 (-5.30%)

Sees FY20 net income…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

FRTA Forterra
$14.12 /

-0.79 (-5.30%)

10/21/20 Exane BNP Paribas
Forterra upgraded to Outperform from Neutral at Exane BNP Paribas
10/19/20 BofA
Forterra initiated with a Buy at BofA
10/19/20 BofA
Forterra initiated with a Buy at BofA
09/24/20 Deutsche Bank
Forterra initiated with a Buy at Deutsche Bank
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

  • 17
    Sep
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

Earnings
Forterra reports Q3 EPS 42c, consensus 48c » 17:52
10/28/20
10/28
17:52
10/28/20
17:52
FRTA

Forterra

$14.12 /

-0.79 (-5.30%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

FRTA Forterra
$14.12 /

-0.79 (-5.30%)

10/21/20 Exane BNP Paribas
Forterra upgraded to Outperform from Neutral at Exane BNP Paribas
10/19/20 BofA
Forterra initiated with a Buy at BofA
10/19/20 BofA
Forterra initiated with a Buy at BofA
09/24/20 Deutsche Bank
Forterra initiated with a Buy at Deutsche Bank
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

  • 17
    Sep
FRTA Forterra
$14.12 /

-0.79 (-5.30%)

Hot Stocks
SPDR Gold Shares holdings fall to 1,258.25MT from 1,266.72MT » 17:52
10/28/20
10/28
17:52
10/28/20
17:52
GLD

SPDR Gold Shares

$176.12 /

-2.91 (-1.63%)

This is the lowest level…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GLD SPDR Gold Shares
$176.12 /

-2.91 (-1.63%)

GLD SPDR Gold Shares
$176.12 /

-2.91 (-1.63%)

Earnings
ChampionX reports Q3 adjusted EPS 3c, consensus (4c) » 17:49
10/28/20
10/28
17:49
10/28/20
17:49
CHX

ChampionX

$7.15 /

-0.43 (-5.67%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CHX ChampionX
$7.15 /

-0.43 (-5.67%)

CHX ChampionX
$7.15 /

-0.43 (-5.67%)

09/16/20 Scotiabank
Scotiabank expands U.S. Oilfield Services coverage with three initiations
09/15/20 Scotiabank
ChampionX initiated with an Outperform at Scotiabank
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Credit Suisse
ChampionX initiated with an Outperform at Credit Suisse
CHX ChampionX
$7.15 /

-0.43 (-5.67%)

CHX ChampionX
$7.15 /

-0.43 (-5.67%)

Earnings
Customers Bancorp reports Q3 core EPS $1.20, consensus $1.01 » 17:48
10/28/20
10/28
17:48
10/28/20
17:48
CUBI

Customers Bancorp

$12.70 /

-0.38 (-2.91%)

Q3 net interest margin,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CUBI Customers Bancorp
$12.70 /

-0.38 (-2.91%)

CUBI Customers Bancorp
$12.70 /

-0.38 (-2.91%)

03/25/20 B. Riley FBR
Customers Bancorp downgraded to Neutral from Buy at B. Riley FBR
CUBI Customers Bancorp
$12.70 /

-0.38 (-2.91%)

Hot Stocks
Teck Resources gets regulatory approval for share buyback » 17:48
10/28/20
10/28
17:48
10/28/20
17:48
TECK

Teck Resources

$12.28 /

-0.28 (-2.23%)

Teck Resources has been…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
TECK Teck Resources
$12.28 /

-0.28 (-2.23%)

TECK Teck Resources
$12.28 /

-0.28 (-2.23%)

11:23 Today BMO Capital
Teck Resources price target lowered to C$21 from C$23 at BMO Capital
11:03 Today Raymond James
Teck Resources price target raised to C$23.50 from C$23 at Raymond James
10:36 Today TD Securities
Teck Resources price target lowered to C$24 from C$25 at TD Securities
10/14/20 Canaccord
Teck Resources price target raised to C$22 from C$20 at Canaccord
TECK Teck Resources
$12.28 /

-0.28 (-2.23%)

TECK Teck Resources
$12.28 /

-0.28 (-2.23%)

Periodicals
Northrop Grumman weighs sale of technology services unit, Bloomberg says » 17:44
10/28/20
10/28
17:44
10/28/20
17:44
NOC

Northrop Grumman

$293.74 /

-8.6 (-2.84%)

Northrop Grumman is…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NOC Northrop Grumman
$293.74 /

-8.6 (-2.84%)

NOC Northrop Grumman
$293.74 /

-8.6 (-2.84%)

10/13/20 Credit Suisse
Northrop Grumman price target lowered to $390 from $400 at Credit Suisse
10/06/20
Fly Intel: Top five analyst upgrades
10/06/20 RBC Capital
Northrop Grumman upgraded to Outperform from Sector Perform at RBC Capital
09/08/20 Morgan Stanley
Northrop Grumman initiated with an Overweight at Morgan Stanley
NOC Northrop Grumman
$293.74 /

-8.6 (-2.84%)

NOC Northrop Grumman
$293.74 /

-8.6 (-2.84%)

NOC Northrop Grumman
$293.74 /

-8.6 (-2.84%)

Hot Stocks
Syneos Health to acquire Synteract » 17:41
10/28/20
10/28
17:41
10/28/20
17:41
SYNH

Syneos Health

$53.24 /

-2.62 (-4.69%)

Syneos Health announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SYNH Syneos Health
$53.24 /

-2.62 (-4.69%)

SYNH Syneos Health
$53.24 /

-2.62 (-4.69%)

10/06/20 Mizuho
Syneos Health upgraded to Buy on attractive entry point at Mizuho
10/06/20 Mizuho
Syneos Health upgraded to Buy from Neutral at Mizuho
10/01/20 Goldman Sachs
Syneos Health upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Truist
Syneos Health price target raised to $80 from $74 at Truist
SYNH Syneos Health
$53.24 /

-2.62 (-4.69%)

  • 16
    Sep
SYNH Syneos Health
$53.24 /

-2.62 (-4.69%)

Hot Stocks
Amgen reports Q3 total product sales up 12% y/y » 17:37
10/28/20
10/28
17:37
10/28/20
17:37
AMGN

Amgen

$216.61 /

-6.78 (-3.04%)

Total product sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AMGN Amgen
$216.61 /

-6.78 (-3.04%)

AMGN Amgen
$216.61 /

-6.78 (-3.04%)

06:22 Today UBS
Amgen initiated with a Neutral at UBS
10/26/20 SVB Leerink
Mirati Therapeutics price target raised to $195 from $134 at SVB Leerink
10/26/20 Piper Sandler
Amgen opportunity not diminished by Mirati data, says Piper Sandler
10/26/20 Raymond James
Amgen upgraded to Outperform from Market Perform at Raymond James
AMGN Amgen
$216.61 /

-6.78 (-3.04%)

AMGN Amgen
$216.61 /

-6.78 (-3.04%)

AMGN Amgen
$216.61 /

-6.78 (-3.04%)

AMGN Amgen
$216.61 /

-6.78 (-3.04%)

Hot Stocks
Ford says warranty costs remain unacceptably high » 17:35
10/28/20
10/28
17:35
10/28/20
17:35
F

Ford

$7.71 /

-0.21 (-2.65%)

Says will deliver first…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
F Ford
$7.71 /

-0.21 (-2.65%)

F Ford
$7.71 /

-0.21 (-2.65%)

10/22/20 JPMorgan
Ford price target raised to $9 from $7 at JPMorgan
10/22/20 Barclays
Ford price target raised to $9 from $8 at Barclays
10/20/20 Citi
Ford price target raised to $9 from $7.50 at Citi
10/14/20 Goldman Sachs
Ford price target raised to $8 from $7 at Goldman Sachs
F Ford
$7.71 /

-0.21 (-2.65%)

F Ford
$7.71 /

-0.21 (-2.65%)

F Ford
$7.71 /

-0.21 (-2.65%)

F Ford
$7.71 /

-0.21 (-2.65%)

Hot Stocks
Discover appoints Shifra Kolsky Chief Accounting Officer » 17:34
10/28/20
10/28
17:34
10/28/20
17:34
DFS

Discover

$62.51 /

-2.75 (-4.21%)

Discover Financial…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DFS Discover
$62.51 /

-2.75 (-4.21%)

DFS Discover
$62.51 /

-2.75 (-4.21%)

10/23/20 BMO Capital
Discover price target raised to $80 from $76 at BMO Capital
10/23/20 RBC Capital
Discover price target raised to $75 from $61 at RBC Capital
10/23/20 Deutsche Bank
Discover price target raised to $74 from $55 at Deutsche Bank
10/09/20 JPMorgan
Discover price target raised to $70 from $54.50 at JPMorgan
DFS Discover
$62.51 /

-2.75 (-4.21%)

DFS Discover
$62.51 /

-2.75 (-4.21%)

DFS Discover
$62.51 /

-2.75 (-4.21%)

DFS Discover
$62.51 /

-2.75 (-4.21%)

Earnings
Stoneridge sees FY21 sales of at least $715M, consensus $602.1M  17:32
10/28/20
10/28
17:32
10/28/20
17:32
SRI

Stoneridge

$22.05 /

-0.45 (-2.00%)

 
ShowHide Related Items >><<
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

02/27/20 Barrington
Stoneridge downgraded to Market Perform on recovery delay at Barrington
02/27/20 Barrington
Stoneridge downgraded to Market Perform from Outperform at Barrington
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

Earnings
Stoneridge sees Q4 EPS (5c) to 5c, consensus 2c » 17:32
10/28/20
10/28
17:32
10/28/20
17:32
SRI

Stoneridge

$22.05 /

-0.45 (-2.00%)

Sees Q4 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

02/27/20 Barrington
Stoneridge downgraded to Market Perform on recovery delay at Barrington
02/27/20 Barrington
Stoneridge downgraded to Market Perform from Outperform at Barrington
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

Earnings
Cousins Properties reports Q3 FFO 69c, consensus 67c » 17:31
10/28/20
10/28
17:31
10/28/20
17:31
CUZ

Cousins Properties

$24.63 /

-1.065 (-4.14%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CUZ Cousins Properties
$24.63 /

-1.065 (-4.14%)

CUZ Cousins Properties
$24.63 /

-1.065 (-4.14%)

06/19/20 Stifel
Cousins Properties removed from Select List at Stifel
CUZ Cousins Properties
$24.63 /

-1.065 (-4.14%)

Earnings
Stoneridge reports Q3 EPS 18c, consensus (15c) » 17:30
10/28/20
10/28
17:30
10/28/20
17:30
SRI

Stoneridge

$22.05 /

-0.45 (-2.00%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

02/27/20 Barrington
Stoneridge downgraded to Market Perform on recovery delay at Barrington
02/27/20 Barrington
Stoneridge downgraded to Market Perform from Outperform at Barrington
SRI Stoneridge
$22.05 /

-0.45 (-2.00%)

Hot Stocks
Golden Star Resources sees 2020 production 187-192koz » 17:28
10/28/20
10/28
17:28
10/28/20
17:28
GSS

Golden Star Resources

$4.01 /

-0.315 (-7.28%)

Sees 2020 CapEx…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

09/11/20 National Bank
Golden Star Resources price target raised to C$8.25 from C$8 at National Bank
09/08/20 Desjardins
Golden Star Resources initiated with a Hold at Desjardins
07/30/20 National Bank
Golden Star upgraded to Outperform from Sector Perform at National Bank
07/29/20 BMO Capital
Golden Star Resources upgraded to Outperform from Market Perform at BMO Capital
GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

Earnings
Golden Star Resources reports Q3 adjusted EPS 17c, consensus 11c » 17:27
10/28/20
10/28
17:27
10/28/20
17:27
GSS

Golden Star Resources

$4.01 /

-0.315 (-7.28%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

09/11/20 National Bank
Golden Star Resources price target raised to C$8.25 from C$8 at National Bank
09/08/20 Desjardins
Golden Star Resources initiated with a Hold at Desjardins
07/30/20 National Bank
Golden Star upgraded to Outperform from Sector Perform at National Bank
07/29/20 BMO Capital
Golden Star Resources upgraded to Outperform from Market Perform at BMO Capital
GSS Golden Star Resources
$4.01 /

-0.315 (-7.28%)

Hot Stocks
Perspecta awarded CalSTRS contract worth up to $42.5M » 17:27
10/28/20
10/28
17:27
10/28/20
17:27
PRSP

Perspecta

$17.63 /

-0.35 (-1.95%)

Perspecta announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PRSP Perspecta
$17.63 /

-0.35 (-1.95%)

PRSP Perspecta
$17.63 /

-0.35 (-1.95%)

06/12/20 William Blair
William Blair sees near-term takeover of Perspecta as unlikely despite Jana news
04/02/20 Wells Fargo
Perspecta price target lowered to $18.50 from $26 at Wells Fargo
03/30/20 William Blair
Perspecta initiated with a Market Perform at William Blair
03/25/20 Wells Fargo
Good news for government contractors in COVID -19 bill, says Wells Fargo
PRSP Perspecta
$17.63 /

-0.35 (-1.95%)

PRSP Perspecta
$17.63 /

-0.35 (-1.95%)

PRSP Perspecta
$17.63 /

-0.35 (-1.95%)

Hot Stocks
ICF International awarded $31M in contracts by HHS » 17:23
10/28/20
10/28
17:23
10/28/20
17:23
ICFI

ICF International

$65.43 /

-2.35 (-3.47%)

ICF was recently awarded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ICFI ICF International
$65.43 /

-2.35 (-3.47%)

ICFI ICF International
$65.43 /

-2.35 (-3.47%)

07/01/20 Berenberg
ICF International upgraded to Buy from Hold at Berenberg
05/18/20 Canaccord
ICF International price target lowered to $80 from $88 at Canaccord
01/15/20 Barrington
ICF International price target raised to $104 from $98 at Barrington
12/19/19 Canaccord
ICF International initiated with a Buy at Canaccord
ICFI ICF International
$65.43 /

-2.35 (-3.47%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.